SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " menstrual " 28 found 🔀 AI-powered Shuffle
Sign in to save shuffle history.
Weight loss surgery can improve reproductive health of women living with obesity
Metabolic bariatric surgery improves menstrual cycle frequency and symptoms of polycystic ovaries in women living with obesity, a new study from the University of Surrey reports.
Your menstrual cycle may affect how well vaccines work
Women who were vaccinated against covid-19 in the luteal phase of their menstrual cycle reported having a breakthrough infection sooner than those vaccinated during their follicular phase
'It's not just an inconvenience': We've underestimated the health impacts of heavy periods
As women have fewer children and more periods, heavy menstrual bleeding is becoming more of a health burden.
Nexira spotlights menstrual health ingredient BloomEase and ViNitrox vascular data at SupplySide Global
New clinical findings show ViNitrox improves Flow-Mediated Dilation by 41% versus placebo — while Nexira enters the longevity segment with NU4LIFE and VinOgrape Plus targeting mitochondrial and microbiome health
ADHD and periods: Are my hormones making my symptoms worse?
A first-of-its-kind study by UK researchers is looking at the link between menstrual cycles and ADHD.
Period poverty: A global menstrual health crisis
500 million women lack menstrual health basics. From Gaza to Ethiopia, CARE is turning period poverty into dignity, one community at a time.
A big assumption has kept women out of health and fitness studies for years. What if it’s wrong?
The assumption that has kept women out of so many physiology studies for years — uncertainty about potential fluctuations due to menstrual cycles or hormonal birth control — turns out to be incorrect.
Bone Health Without the Hype
I am at the Australasian Menopause Society meeting and we had a fantastic lecture on Bone Health on Day 2, called, “Everything you need to know about bones - except the boring bits!” Spoiler alert, there were no boring bits. The lecture was given by Dr. Amanda Beech, who is a senior staff specialist in Obstetric Medicine and Endocrinology at the Royal Hospital for Women, where she is director of the Bone Density Unit. I want to summarize my top 10 take-aways for you. Share Osteoporosis is a disease of low bone mass, disruption of bone microarchitecture, and fragility of the skeleton. It is a silent disease…until someone develops a fracture. The diagnosis of osteoporosis is based on either fragility/minimal trauma fractures or a T-score of less than -2.5 on a DXA (Dual-Energy X-ray Absorptiometry) or bone scan. It is important to recognize that about 50% of minimal trauma fractures occur when women have low bone mass (often referred to as osteopenia), but not osteoporosis. This tells us that bone strength is more complicated than a number on a DXA report. I am going to add a little here that wasn’t in the talk (one can only include so much in 25 minutes), as many women might read the above paragraph and think, “Shouldn’t we be treating everyone with low bone mass if this is when 50% of the fractures occur?” Many fractures happen for women with low bone mass because there are so many women with low bone mass –it is a statement about the population on a whole, not about the fracture risk of low bone mass. For you as an individual, bone density is only one component of fracture risk and many women with lower bone mass will not have a significantly elevated fracture risk. This is why individualized risk assessment matters. Subscribe We build bone in our teens and twenties, and by the time we are about thirty we have reached peak bone mass. This is why, when we discuss risk factors for osteoporosis, it is important to consider factors that might have affected us in our teens and twenties when we were actively building bone, such as nutritional restriction/energy imbalance. It is important to ask women about a history of eating disorders, and for those with such a history, getting a bone scan in perimenopause or at age 50 is likely warranted. (This image below isn’t from the talk, but is similar to one that was). Bone mass is relatively stable until about two years before the final menstrual period, and perimenopause marks a time of rapid bone loss for women. Using urinary markers of bone loss we know that the time of significantly accelerated bone loss starts about 1 year before the final period and ends about 2 years after the final period. The Study of Women’s Health Across the Nation (SWAN) shows that over the menopause transition women lose an average of 10.6% of the bone at their lumbar spine and 9.1% at the femoral neck While this wasn’t covered in the lecture, I want to add that the rapid bone loss during perimenopause is clearly related to more than estradiol, because during this time estradiol levels can be erratic and not uniformly low. Bone loss during perimenopause is likely a multi-hormone event. For example, rising FSH (follicle stimulating hormone) tracks with bone loss better than estradiol, and there is evidence that FSH may act directly on bone. While decreased estrogen matters, there is clearly more going on. FSH and bone is an active area of research. Subscribe Screening for osteoporosis was recommended fairly broadly before age 65, and was taken from the “Practitioner’s Toolkit for Managing Menopause,” from Monash University. Here is a screenshot from the toolkit that was used as a slide: I am going to add a little bit more about body weight here for clarification. Low body mass (typically 152.1 lb): 0 points (risk neutral) 60–69 kg (132.3–152.1 lb): 3 points (adds some risk)
Scientists cited by Heritage Foundation report on women’s sports say it misrepresented their research
The conservative think tank’s report claims that high-intensity and elite sports training has lasting effects on menstrual cycles and fertility
Penn researchers use AI to surface unreported GLP-1 side effects in Reddit posts
Could mining Reddit with AI help spot drug side effects earlier? A new Penn study suggests it might. Using large language models to map patient posts to standardized medical terms, researchers analyzed more than 400,000 Reddit posts about GLP-1s and found both known side effects and possibly underrecognized symptoms, like menstrual changes. The team says the approach could eventually help generate early safety signals for other drugs and wellness trends discussed online.
'It's a very unique biological specimen': The scientists using menstrual blood to diagnose diseases
From diagnosing endometriosis and cervical cancer to diabetes, vitamin D deficiency, and pollution exposure, here's what menstrual blood can reveal about your health.
Global Health & WASH: May 2026 Funding Opportunities (14 new opportunities!)
The May update for Global Health & WASH brings new calls that cluster around three distinct shifts: LMIC research leadership moving from funder encouragement into a hard eligibility constraint, pharmaceutical and corporate-linked funders running structurally independent education and use-inspired research portfolios at substantial scale, and AI adoption shifting decisively from speculative tool to operational capability across health and WASH systems alike. In LMIC Research Leadership as Eligibility, Not Encouragement, Wellcome anchors the dominant signal of the month with three separate major calls that all require or strongly center LMIC leadership in their basic eligibility architecture. Wellcome’s ESIC Hubs (£1.5-£1.9M per hub over 3-5 years) explicitly requires an LMIC-based lead applicant, treating Global South leadership as a design constraint rather than a participation goal. Wellcome’s Infectious Disease Clinical Trial Development Award funds transdisciplinary teams whose lead must be a mid-career or established researcher based at an organization in Africa, South Asia, or Southeast Asia. Wellcome’s larger Infectious Disease Clinical Trial Award (£1M-£8M for optimizing licensed interventions) requires the administering organization to be in eligible LMIC regions and at least 50% of applicants based there. Around Wellcome, the same pattern shows up at smaller scale and across funders: CHINNOVA channels $1M into West and Central African research institutions for climate-health work; IBRO’s Neuroscience Training Grants explicitly tier ceilings by region of residence with Africa receiving the highest amount ($5,000); IHME’s GBD Emerging Researcher Award reserves at least one of its two annual awards for an LMIC researcher; Sidaction’s HIV Cure call funds research teams across France, the Netherlands, and eligible African countries with a minimum two-country collaboration requirement. Taken together, these calls signal a meaningful shift in how research equity is being operationalized — not as encouragement language at the bottom of a call, but as a structural feature of who can lead, where the work must be administered, and what proportion of the team must be regionally rooted. In Pharma-Funded Independent Medical Education and Use-Inspired Research, the lineup this month is unusually deep. Pfizer alone runs four parallel calls under independent education and quality improvement frameworks: a Migraine and Women’s Health RFP (200K x 2-year, $500K pool), Migraine IME ($200K, $1M pool), JAK Inhibitor evidence-based education ($100K), and Maternal Vaccination HCP Education in Saudi Arabia ($75K), plus a separate Pediatric Pneumococcal Surveillance research call in Saudi Arabia ($400K per project). Novo Nordisk Foundation runs four parallel calls of its own at substantial scale: Infectious Diseases Catalyst Grants (DKK 60M pool, up to DKK 7M collaborative), Non-Diabetic Endocrinology Collaborative Grants (DKK 53M pool, DKK 5-10M per project), Pioneer Innovator Grant Health (DKK 1.1M), and Distinguished Innovator Grant Health (DKK 6.8M). LEO Foundation deploys DKK 2-4M per project for dermatology research excellence. Pfizer’s framing across calls deliberately separates the funding from product promotion, emphasizing measurable practice-relevant change and structural distance between scientific outputs and commercial activity. Novo Nordisk’s “use-inspired” hard filter pushes researchers toward a credible translation pathway from mechanism to deployable tool. The pattern: industry-aligned funders are running structurally independent portfolios at meaningful $ that fund implementation evidence, not promotion. In AI as Operational Capability, Not Speculation, several calls this month explicitly treat AI adoption as a near-term operational question with real evidence and governance requirements, rather than a speculative trend to be watched. Wellcome’s ESIC Hubs frames AI as “the accelerator” for evidence synthesis, asking hubs to translate technical innovation into adoption-ready workflows that can match real-world policy timelines. UNICEF Venture Fund’s new Climate Tech for Children’s Health call funds for-profit startups deploying AI, machine learning, and blockchain in low-resource environments, with a strict requirement that solutions must already have a working prototype with promising pilot results. The Water Research Foundation has launched two simultaneous AI calls treating reproducibility, cybersecurity guardrails, and human-in-the-loop deployments as core design constraints rather than nice-to-haves: one on GenAI and Agentic AI in water utilities ($200K), one on alternatives to water shutoffs that explicitly screens for implementation economics evidence. Nordic Innovation’s quantum technology call (NOK 4.5M) extends the same logic into life science and healthcare, demanding consortium-stage projects mature enough to test with real users. TEF-Health offers €300K in subsidized testing infrastructure for European healthcare AI and robotics SMEs. The pattern: funders are converting AI pilots into playbooks, requiring transfer evidence and risk controls before AI can move from experimentation to sector-wide operational practice. For LMIC-based researchers in infectious disease or evidence synthesis, the three Wellcome calls together represent the deepest concentration of LMIC-led research capital in recent memory — pair the Infectious Disease Clinical Trial Development Award (£200K, deadline May 19) as a strategic pipeline feeder into the larger Infectious Disease Clinical Trial Award (£1-£8M, deadline June 2), since the development award functions explicitly as a track into the larger trial scheme. For Nordic researchers, the four Novo Nordisk Foundation calls plus LEO Foundation and Nordic Innovation Quantum represent ~$30M in regional research capital this cycle, all with deadlines clustered in May-August. For WASH practitioners, the three Water Research Foundation calls together (each up to $200K) are a cluster worth reading across — one on AI deployment, one on shutoff alternatives, one rewarding applied innovation — and the strongest applicants will articulate how their work bridges utility operations to policy-relevant evidence. For US-based clinical researchers and educators, the four Pfizer calls plus the APF Portfolio’s 80+ programs form an unusually accessible recurring pipeline; APF’s prohibition on indirect costs is a meaningful structural feature for early-career applicants whose institutions might otherwise absorb significant overhead. Snapshot of New Opportunities Total Estimated Funding Pool: $100 Million+ USD The grants are organized into three categories: Open Calls: Current grant and opportunities with a deadline. Grants are listed by closing date. 39 open opportunities- 14 new! Rolling Applications: current grant and opportunities with rolling applications (but it’s still best to submit as early as possible). 14 rolling opportunities- 1 new opportunity! Long term planning: Grants that have closed their current rounds, but are expected to open new windows. 4 long term opportunities! A quick tip for returning readers: if you want to jump straight to the newest additions, use CTRL F to search for “New!” and navigate quickly to the latest funding opportunities This post is for paid subscribers. This helps support the time and effort it takes to curate and organize these opportunities. Subscribe To keep this accessible to everyone who needs it, we’re happy to offer pay what you can rates. You can find more details here. Open Calls: Migraine Competitive Grant Program: Migraine and Women’s Health (Quality Improvement and/or Research RFP), Pfizer.*Closing soon!* Pfizer, in collaboration with the American Headache Society, is seeking independent quality improvement and research projects that close persistent gaps in migraine care for women across the United States. The funding logic centers on measurable, practice-relevant change: proposals should generate actionable evidence, tools, or system improvements that can be shared and used widely, not just within a single site. Priority areas span menstrual migraine and screening in women’s health settings, the role of hormonal fluctuations across the lifespan, sex-specific risk factors, comorbidities and quality-of-life burden, and disparities in outcomes by race, ethnicity, and socioeconomic status. The call is structured as a two-step competitive process with an initial Letter of Intent, with the strongest concepts expected to translate scientific insight into implementable improvements in diagnosis, management, and equity. Geographies: United States. Who can apply: U.S.-based organizations (not individuals), including professional schools, healthcare institutions, professional organizations, and other entities focused on healthcare improvement. Funding amount: Up to USD $200,000 total over 2 years; total pool USD $500,000. Targeted Sectors / SDGs: Health; Focus areas: migraine, women’s health, quality improvement, clinical research, menstrual migraine, health disparities. Deadline: LOI: May 5, 2026; Full proposal (by invitation): August 28, 2026. Learn more and apply here. This RFP rewards “shareable impact”: the most competitive submissions will pair rigorous methods with a clear plan for system uptake and dissemination beyond the originating institution. ReSSARC: Strengthening the Health Sector and Food Security in the Central African Republic (AID 013381/01/0) Call for Proposals, Italian Agency for Development Cooperation (AICS). *Closing soon!* AICS is seeking a limited set of high-capacity humanitarian partners to deliver an integrated package that stabilizes essential health services while reducing acute malnutrition and strengthening food security resilience in priority areas of the Central African Republic. The funder’s logic is explicitly nexus-based: proposals should meet urgent, life-saving needs while reinforcing local systems, coordination mechanisms, and community-level capacity so results persist beyond the emergency window. AICS emphasizes inclusion and protection outcomes, expecting gender-sensitive design and explicit measures for groups facing compounded vulnerability, including women, children under five, internally displaced people, and people with disabilities. The call also signals a localization pathway, encouraging stronger collaboration with national NGOs and balanced partnerships, alongside clear coordination with existing cluster and humanitarian actors to minimize duplication and improve coverage. Geographies: Central African Republic (Bangui, Ombella-Mpoko, Ouham, Ouham-Pende, Lim-Pende, Lobaye). Who can apply: Non-profit organizations registered with AICS, plus eligible non-profits without an office in Italy that have a pre-existing collaboration agreement with an AICS-listed organization. Funding amount: Total pool EUR €1,800,000; max EUR €800,000 (single applicant) or EUR €1,000,000 (ATS). Targeted Sectors / SDGs: Health; Focus areas: malnutrition prevention and treatment, maternal and child health, community health services, food security and resilience, localization partnerships Deadline: May 5, 2026. Learn more and apply here. This call is structured to reward partners who can link frontline service delivery to system durability and localization, not just short-term coverage gains. Contracts for Innovation in drug and alcohol addiction healthcare, Innovate UK. *Closing soon!* Innovate UK, on behalf of the Office for Life Sciences Addiction Healthcare Goals program, is procuring R&D to accelerate innovations that can improve treatment outcomes, strengthen recovery, and reduce harm and deaths linked to drug and alcohol addiction. The competition is positioned as a market-facing readiness push: selected projects are expected to advance solutions toward later-stage validation, generate evidence of user acceptability and UK market fit, and map credible routes through regulatory and certification requirements. Innovate UK signals a preference for innovations that can be field-tested in relevant UK settings and progressed to TRL 6 or 7, with practical plans for commercialization after contract completion. This structure favors applicants that can execute most work in-house, co-develop with service providers and people with lived experience, and translate technical progress into deployable tools for addiction healthcare delivery. Geographies: United Kingdom. Who can apply: Single organizations of any size (including EU, EEA, or international) leading delivery, with most work and key deliverables carried out in the UK; subcontractors for specialist skills only. Funding amount: GBP £200,000–1.5 million per project (inclusive of VAT); Total pool: GBP £20 million (across two strands). Targeted Sectors / SDGs: Health; Focus areas: Mental Health, Health Systems Strengthening, Research & Development, Technology Access. Deadline: May 6, 2026 (11:00am). Learn more and apply here. This call uses procurement to pull near-market addiction innovations toward operational proof and adoption pathways in UK services.
Could the secret to diagnosing endometriosis be hiding in plain sight?
Although menstrual blood is typically discarded, researchers are beginning to use it to reveal new clues about women’s health.
Appleton mayor issues proclamation for 'period poverty' and menstrual health awareness
The mayor of Appleton is shining a spotlight on menstrual health equity and the importance of making sure everyone has access to period products.
Life with PMDD: 'Like the Grim Reaper coming every month'
Women diagnosed with premenstrual dysphoric disorder discuss how it impacts their lives.
FDA releases report on toxic metals in tampons and potential health risks
Previous research had raised safety worries over whether metals such as arsenic and lead in menstrual products could pose health risks.
AI scans 400,000 Reddit posts and finds hidden Ozempic side effects
By analyzing over 400,000 Reddit posts, researchers discovered that users of popular GLP-1 weight-loss drugs frequently discussed unexpected symptoms like menstrual irregularities, chills, and hot flashes. The findings suggest AI could turn social media into a powerful early-warning system for spotting side effects that clinical trials may miss.
Contraception For Teens: Let's Talk About It
By Mahvash Madni, MD, FAAP HealthDay ReporterSATURDAY, May 30, 2026 (HealthDay News) — Contraception is not just about preventing an unwanted pregnancy. Experts say it’s also an important part of adolescent health care, helping regulate menstrual cycles, manage painful symptoms and treat some hormone-related conditions. Understanding the ...
How Perimenopause Became America's New Health Scare
If you’re a woman who speaks English, it sometimes feels like you can’t spend time on the internet without being bombarded with all the ways in which your body or your mind could be just a little broken. A few years ago, Instagram was full of women talking about attention deficit disorder, and lo and behold: From 2020 to 2022, the percentage of women (between the ages of 23 and 49) newly diagnosed with it nearly doubled. Not long ago, premenstrual syndrome was all the rage, with the algorithm pushing videos that explained why it’s okay to fly off the handle once a month. These days, the word perimenopause is everywhere. Perhaps you’ve seen the headlines. “Perimenopause is having a millennial moment. Here are 7 ways to cope,” says The Washington Post. Or perhaps you’ve seen Apple TV’s glossy drama Your Friends & Neighbors, which is back for its second season; the female protagonist Mel is explicitly perimenopausal, and in the first season, she keyed a car for no apparent reason. She’s played by Amanda Peet, who talks about being perimenopausal in real life (“God knows I’ve wanted to key a lot of cars in the last three years,” she’s said.) In fact, it sometimes feels like every celebrity interview with a forty- or fiftysomething woman requires her to open up about what’s going on with her hormones. Drew Barrymore joked on CBS Mornings that when she found out how long perimenopause can last, she thought she’d “never make it 10 years like this.” Katherine Heigl told Business Insider that “whoever designed it so that women would be going through perimenopause while raising teenagers should be sent a strongly worded letter.” At the same time, influencers who talk about perimenopause seem to have cropped up out of nowhere with something to sell you, causing people online to wonder where this all came from. It’s trickled down from Instagram to tchotchke shops, which sell fridge magnets that say “Perimenopause Is Hot.” You can buy a T-shirt that proclaims “Perimenopause Made Me Do It!” My mom, who is 48, started uncontrollably shaking her leg at night a few years ago. “It’s perimenopause,” she told me when I complained about how annoying it was. But what exactly is perimenopause—and why are we all talking about it all of a sudden?
Ennature Biopharma Advances Women’s Health Science With Fast-Acting Shatavari and Sustained-Release Ginger
NOIDA, India, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Ennature Biopharma is expanding the clinical evidence for its Aspargize and Gingeren botanical ingredients, addressing two distinct areas of women’s health: menopause and menstrual health. The botanical formulations pair Shatavari for menopausal support with sustained-release ginger for menstrual comfort. The findings come amid growing interest in evidence-based women’s health solutions and ahead of World Menopause Month and SupplySide Global in O
Menstrual tracking apps lack evidence of health and performance benefits
Digital menstrual tracking risks creating more harm than benefit and requires greater scrutiny, warn experts in The BMJ today.
Your period may make sport injuries more severe
Professional footballer players who became injured while on their period took longer to recover than when injuries occurred at other times of their menstrual cycle
Nexira spotlights science-backed solutions for women’s health
Women’s health is expanding through hormone-focused, lifecycle nutrition. At Vitafoods Asia, Nexira launches BloomEase, a science-backed solution combining botanicals and marine magnesium to support premenstrual syndrome and improve women’s comfort and well-being
The Internet Is Obsessed With Ovulation
What’s so great about a “natural” menstrual cycle?
People are taking allergy and heartburn pills for PMS. Could it work?
Can the mix really help with premenstrual woes? Theoretically, the link between histamine and hormones could explain why the trendy DIY treatment seems to help some women.
Oura launches a proprietary AI model focused on women's health
The model supports questions spanning the full reproductive health spectrum, from early menstrual cycles through menopause.
Oura launches a proprietary AI model focused on women's health
The model supports questions spanning the full reproductive health spectrum, from early menstrual cycles through menopause.
HEALTH Yeah! Episode 32: Heavy Bleeding and Pelvic Pain
Learn what’s normal — and not — with menstrual cycles, heavy bleeding, pelvic pain and women’s health care at Stony Brook Medicine.